HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $35 price target.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
5 Value Stocks In The Healthcare Sector
What is a Value Stock?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
Gainers
Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.
Why GreenBox POS Is Trading Higher By Around 72%, Here Are 70 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
GreenBox POS (NASDAQ: GBOX) shares jumped 72.4% to $2.19 as the company reported better-than-expected Q2 sales.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 34.4% to $2.81 during Thursday's after-market session. The market value of their outstanding shares is at $29.0 million.
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results And Updated Financial Guidance
TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpected
RECIST responses observed with TPST-1120 combined with